期刊
FRONTIERS IN ONCOLOGY
卷 3, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2013.00322
关键词
glioblastoma; immunotherapy; T-cell therapy; genetically modified T cells
类别
资金
- NIH [1R01CA148748-01A1, 1R01CA173750-01, P01CA094237, CPRIT RP110553]
- Alex's Lemonade Stand Foundation
- Dana Foundation
- James S. McDonnell Foundation
- NATIONAL CANCER INSTITUTE [R01CA173750, P01CA094237, R01CA148748] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL092332] Funding Source: NIH RePORTER
Despite advances in surgical procedures, radiation, and chemotherapy the outcome for patients with glioblastoma (GBM) remains poor. While GBM cells express antigens that are potentially recognized by T cells, GBMs prevent the induction of GBM-specific immune responses by creating an immunosuppressive microenvironment. The advent of gene transfer has allowed the rapid generation of antigen-specific T cells as well as T cells with enhanced effector function. Here we review recent advances in the field of cell therapy with genetically modified T cells and how these advances might improve outcomes for patients with GBM in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据